Designation: Received FDA Fast Track designation yesterday for QRX003 for Netherton Syndrome, adding to existing Pediatric Rare Disease and Orphan Drug designations. QRX003 is a 4% lotion formulation targeting this rare genetic skin disorder.

Update: Holland & Knight notes that MDUFA VI negotiations are entering their final phase this month. Key themes include the potential expansion of the Third-Party Submission Program (TAP 2.0) and intense discussions around "America First" facility fee waivers for domestic generic manufacturers.

Data: Presented detailed 3-year EMBARK data at MDA 2026 yesterday in a late-breaking oral presentation. The extended follow-up showed Elevidys-treated patients maintained NSAA scores above baseline at year three, while external controls continued their expected decline. The company reported a 73% slowing of time-to-rise and a 70% slowing of 10-meter walk/run versus external controls, strongly reinforcing the durability signal for the DMD gene therapy.

Update: Released a CEO Corner update yesterday on MIRACLE trial progress. Treatment of the initial 45-patient cohort is expected to enable unblinding data later this quarter for this pancreatic cancer study evaluating WP1066.

Strategy: Executives are attending ATTD 2026 in Barcelona this week, showcasing the company's CGM+ continuous glucose monitoring platform and discussing potential partnerships. The company is targeting a 2026 pivotal trial start.

Funding: Extended its Series A to $100M yesterday, adding $40M to its original May 2025 raise. Frazier Life Sciences joined as a new investor.

Milestone: The company announced the first patient dosed in its Phase 2 dystonia trial evaluating VIM0423. A Phase 2 Parkinson's disease trial is planned for mid-2026.

Partnership: Selected Cincinnati Children's Advanced Gene & Cell Therapy Center (AGCTC) as the manufacturing partner for TPST-2003, a dual-targeting CD19/BCMA CAR-T for relapsed/refractory multiple myeloma. Tech transfer is expected to complete in Q3 2026 with an IND filing targeted for Q4 2026.

M&A: Announced Sunday a $950M definitive agreement to acquire Biocare Medical, aggressively expanding its pathology solutions portfolio with IHC, ISH, and FISH technologies.

M&A: Announced Monday the acquisition of Ostro, an AI-driven brand engagement platform for pharma, for approximately $100M in cash and long-term equity retention grants.

Security Threat: Stryker confirmed yesterday a cyberattack affecting its global Microsoft environment. Pro-Iran group Handala claimed responsibility, citing retaliation for the Minab school strike.

Impact: While Stryker stated there is no indication of ransomware or malware deployment, the incident underscores the escalating, state-sponsored cybersecurity vulnerabilities across the global medtech sector.

Layoffs: Announced plans to cut approximately 800 positions as part of its "Horizon" restructuring program, adding to 600 positions eliminated between March 2024 and June 2025. The company will close four sites, consolidating its footprint to 10 locations globally.

Data: United for Medical Research released its 2026 annual NIH economic impact report, finding that $36.58B awarded in FY2025 generated $94.15B in economic activity—a massive return of approximately $2.57 for every $1 invested.